The aim of this article is to review the current clinical evidence for liraglutide compared with other injectable therapies commonly initiated after failure of oral therapy, including other GLP-1 mimetics and basal insulin within the context of the NICE guidelines, in order to provide further guidance to physicians treating patients with T2DM who have failed on oral therapy. This evidence concerns the gene INS and type 2 diabetes mellitus.